First patients in Spain to be treated with Pepaxti

STOCKHOLM – May 27, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced that the first Spanish hospital will begin treating patients with Pepaxti.

The first order of the drug from a Spanish hospital follows the availability of Pepaxti in the Spanish healthcare system (“Nomenclator”), making it possible for healthcare providers to in certain cases order the product before regional access has been negotiated.

“The reception of this innovation in the medical community is a testament to the unmet medical need that this drug fills,” says Sofia Heigis, CEO of Oncopeptides. “We look forward to more patients and professionals both in Spain and the rest of Europe benefitting from the clinical and quality of life results demonstrated by this treatment.”

In total, 16 Spanish hospitals and more than 100 patients have participated in the clinical trials that have led to the approval of the first drug in the peptide conjugate class for the treatment of relapsed, refractory multiple myeloma.

For more information, including questions and answers for investors, please visit Oncopeptides’ website.